Ipsen becomes the latest pharma to expand in Ireland, with a $50M investment in its facility in Dublin suburbs
It is no secret that Ireland has become a hot spot for pharma manufacturing projects over the past year, and it seems that Ipsen will be the latest player to get in on the action.
On Monday Ipsen unveiled the €52 million ($49.9 million) expansion it made into its active pharmaceutical ingredient manufacturing facility in Blanchardstown, a small suburb of Dublin. The investment is aimed at boosting medicine and ingredient production in cancer and rare disease space.
According to the Industrial Development Agency of Ireland, the Ipsen site has already scaled API production by 10% and is looking to pump even more improvements into the facility. The company is looking at investing another €15 million ($14.1 million) in Blanchardstown over the next three years, upgrading technology and installing more sustainability efforts.
While no details were given on the exact size or what the growth in headcount is, an Ipsen Ireland executive stated that the site currently employs 175 employees and has grown its workforce by 20% in the past three years, particularly in manufacturing and R&D.
Endpoints News did reach out to Ipsen for more details on the expansion, but did not receive a response by press time.
“The Irish market plays an important role as part of Ipsen’s international network and Ipsen is committed to continued investment and innovation in Ireland to support improved care for patients across the therapeutic areas we serve – oncology, rare disease, and neuroscience. This new investment in Dublin is a milestone in our ongoing journey of innovation and our growing footprint in Ireland,” Ipsen CEO David Loew said in a statement.
The site itself has been in use by Ipsen since 1989 as a manufacturing site and an R&D hub — mainly in the development of APIs.
However, Ipsen is just the latest company to expand its presence on Irish soil. On Thursday, AbbVie kicked off a €60 million ($58.9 million) into its tablet and capsule manufacturing site in the town of Carrigtwohill, Ireland, a suburb of Cork City in the south of Ireland.
The Dublin area is also seeing several expansions from pharma companies including Alexion, who is injecting €65 million ($62.4 million), across two sites, one also in Blanchardstown and another site at the Monksland Industrial Park in the Irish town of Athlone. South Korean conglomerate SK’s CDMO arm is also making an investment in Dublin in the form of $35 million to expand its pharmaceutical manufacturing plant in the Dublin suburb of Swords.
Abbott, J&J, Eli Lilly, Horizon and Cambrex are also just some of the other companies that are committing to multimillion-dollar projects in Ireland this year.